MMIT Blog

MMIT Reality Check on Breast Cancer HER2- (Aug 2019)

Trends That Matter for Medicare Part D Costs

Radar On Market Access: More Than 1,000 RM/AT Products Are in Pipeline

Radar On Market Access: Trump's Drug Importation Plan Faces Significant Hurdles

MMIT Reality Check on Ulcerative Colitis (Aug 2019)

Perspectives on Electronic Real-Time Benefit Tool

Radar On Market Access: Senate Drug Pricing Legislation Takes Wide-Reaching Approach

Radar On Market Access: Congress Eyes Measures That Could Affect PBMs

MMIT Reality Check on Merkel Cell Carcinoma (Aug 2019)

Trends That Matter for CMS's Oncology Care Model

Radar On Market Access: Can Louisiana’s Hepatitis C Drug Payment Model Be Replicated?

Radar On Market Access: Will Blockchain Transform Relationships Industry Wide?

MMIT Reality Check on Parkinson's Disease (Jul 2019)

Perspectives on New York's Pricing Transparency Bill

Radar On Market Access: Post-Rebate Rule, Trump Administration Mulls 'Any and All Tools'

Radar On Market Access: Plans Offer More $0 Copay Drugs to Boost Adherence

MMIT Reality Check on Kidney Cancer (Jul 2019)

Trends That Matter for Oncology Biosimilars Management

Radar On Market Access: In Win for Managed Care, Trump Administration Drops Rebate Rule

Radar On Market Access: In Medicare Part D, Generic Drugs May Not Always Be Cheaper

MMIT Reality Check on Bipolar Disorder (Jul 2019)

Perspectives on the First NASH Drugs

Radar On Market Access: Plans Must Cover PrEP at No Cost After USPSTF Recommendation

Radar On Market Access: Expensive Drugs Launched After OCM Baseline Period Are Hamstringing Providers, Study Shows

MMIT Reality Check on Psoriatic Arthritis (Jul 2019)

Trends That Matter for Oncology

Radar On Market Access: States Plow Ahead on 'Subscription' Models for Hep C Therapy

Radar On Market Access: New York Bill Targets on Pricing Transparency from PBMs

MMIT Reality Check on Acute Lymphoblastic Leukemia (Jun 2019)

Perspectives on Express Script's "Digital Health Formulary"

Radar On Market Access: CMS Requires Part D Plans to Offer RTBT

Radar On Market Access: Troy Medicare Aims to Launch Pharmacist-Centered Model in NC

MMIT Reality Check on Hemophilia A or B With Inhibitors (Jun 2019)

Trends That Matter for COPD Medications

Radar On Market Access: Magellan Rx Initiates Oncology Biosimilars Program

Radar On Market Access: Payers Are Wary as First NASH Drugs May Hit U.S. Market Soon

MMIT Reality Check on Ankylosing Spondylitis (Jun 2019)

Perspectives on CMS's Drug Pricing Proposals

Formulary Search Rebrand Enhances the Big Picture, Adds Medical Benefit View

Radar On Market Access: Outstanding Part D Proposals Created Uncertainty in 2020 Bid Process

Radar On Market Access: Payers Will Likely Use Various Tactics to Manage Zolgensma

MMIT Reality Check on Urothelial/Bladder Cancer (Jun 2019)

Trends That Matter for Use of Biologics

Radar On Market Access: Oncology Is Experiencing Surge Of Innovation — and Prices

Radar On Market Access: Blues Plans Promote Alternative Treatments to Combat Opioid Epidemic

MMIT Reality Check on Endometriosis (May 2019)

Perspectives on Diabetic Drug’s Kidney Benefit

Radar On Market Access: Express Scripts Takes on Industry's Digital Transformation

Radar On Market Access: CMS 'Meaningfully Walks Back' on Key Drug Pricing Proposals

MMIT Reality Check on Pain Narcotic Opioid (May 2019)

Trends That Matter for Infliximab Biosimilars

Radar On Market Access: Study Examines Effects of Strategies in SBS Management

Radar On Market Access: Generic Advair May Help Reduce COPD Costs

MMIT Reality Check on Chronic Idiopathic Constipation (May 2019)

Perspectives on BioScrip/Option Care Deal

Radar On Market Access: Use of Biologics, Biosimilars Showed Rapid Uptake in 2018

Radar On Market Access: CBO Says Proposed Rebate Rule Will Cost Government $177B

MMIT Reality Check on Narcolepsy (May 2019)

Trends That Matter for Colorectal Cancer Medications

Radar On Market Access: CMS Extends Options to States to Test Innovative Dual-Eligible Care Models

Radar On Market Access: Magellan Sees Success With Infliximab Biosimilars

MMIT Reality Check on Low Testosterone (May 2019)

Perspectives on New Postpartum Depression Drug

Radar On Market Access: Calif. Insurers Fear lll Effects if Medicaid Pharmacy Is Carved Out

Radar On Market Access: Diabetic Drug’s Kidney Benefit May Not Be Game-Changer

MMIT Reality Check on Anemia — Chronic Kidney Disease (Apr 2019)

Trends That Matter for Insulin

Radar On Market Access: CMS Guidance on Rebate Shift Offers Transition for Part D Plans

Radar On Market Access: Copay Accumulators’ Use Rises; Virginia Passes Law Banning Such Programs

2019 Specialty Pharmacy Patient Choice Awards Finalists Announced

MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2019)

Perspectives on Insulin Management

Radar On Market Access: CMS Finalizes Medicare Rates, Unveils '20 Opioid Policies

Radar On Market Access: PBM Trade Group Offers Alternative to Proposed Drug Rebate Changes

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2019)

Trends That Matter for Cancer Care

Radar On Market Access: BioScrip, Option Care Will Join Forces Within Infusion Market

Radar On Market Access: Drugmakers Are Trying Array of Tactics to Counter Copay Accumulator Programs

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2019)

Perspectives on the First-Ever Digital Oncology Medicine

Radar On Market Access: Insurer Tools Aim to Help Members Save on Prescription Drugs

Radar On Market Access: New Postpartum Depression Drug Presents Payer Challenges

MMIT Reality Check on Opioid Dependence (Mar 2019)

Trends That Matter for Cystic Fibrosis Medications

Radar On Market Access: Colorado Soon Will Tighten Rules for Short-Term Plans

Radar On Market Access: Magellan’s PBM Could Be Attractive Acquisition Target

MMIT Reality Check on COPD (Mar 2019)

Perspectives on Novel Drug Management in 2019

Radar On Market Access: As Insulin Prices Balloon, Insurers Try to Offer Some Relief

Radar On Market Access: Civica Rx Aims to Provide 14 Drugs in Short Supply in '19

MMIT Reality Check on Glaucoma (Mar 2019)

Trends That Matter for Drug Spending

Radar On Market Access: Oncologists Are Concerned With Patients’ Refusal of Treatment

Radar On Market Access: Firms Are Teaming Up to Offer First Digital Oncology Medicine

MMIT Reality Check on Major Depressive Disorder (Mar 2019)

Perspectives on Biosimilars Market in 2019

Radar On Market Access: What Is Behind CVS Health’s LTC Woes?

Radar On Market Access: Diplomat Pharmacy Postpones Earnings Release Amid PBM Struggles

MMIT Reality Check on Hereditary Angioedema (Mar 2018)

Trends That Matter for California Medicaid Program

Radar On Market Access: Highmark Expands Proving Ground for Innovative Therapies

Radar On Market Access: As Cystic Fibrosis Costs Rise, Payers Seek New Strategies

MMIT Reality Check on HIV (Feb 2019)

Perspectives on California's Plan to Move Medicaid Pharmacy Purchasing to FFS

Radar On Market Access: PBMs Prepare for Big Changes Tied to Part D Rebate Rule

Radar On Market Access: Express Scripts Reports Record Low Drug Trend Across Commercial Plans in 2018

MMIT Reality Check on Rheumatoid Arthritis (Feb 2019)

Trends That Matter for M&A Activity in Specialty Pharmacy and Infusion Therapy Spaces

Radar On Market Access: Novel Drugs, High Prices, Ways to Manage Them Remain Hot

Radar On Market Access: Part D Rebate Proposal Might Raise Premiums, Reshape PBMs' Business Models

MMIT Reality Check on Type 2 Diabetes (Feb 2019)

Perspectives on PBMs' Business Model in State Medicaid Programs

Radar On Market Access: Biosimilars Market Is Picking Up Steam, Could See Boom Soon

Radar On Market Access: Anthem Hits the Gas on Launch of In-House PBM IngenioRx

MMIT Reality Check on Neutropenia (Feb 2019)

Trends That Matter for Hep C Treatment

Radar On Market Access: California Makes Waves With Pharma Benefits, Purchasing Plan

Radar On Market Access: 2018 Saw Slowing M&A Activity; Expect More of the Same in ’19

MMIT Reality Check on Hemophilia (Jan 2019)

Perspectives on New MA Rule That Touches Protected Classes

Radar On Market Access: Specialty Drug Pipeline Holds Promise Amid High Costs

Radar On Market Access: Drug-Pricing Transparency, Vertical PBM Deals Are Top of Mind for Employers in 2019

MMIT Reality Check on PCSK9 (Jan 2019)

Trends That Matter for FDA Orphan Label Application Reviews

Radar On Market Access: Vermont Pushes Ahead on Canadian Drug Importation

Radar On Market Access: Don’t Expect Major Action on Drug Prices in 2019, Experts Say

MMIT Reality Check on Multiple Sclerosis (Jan 2019)

Perspectives on Potential Humana/Walgreens Tie-Up

Radar On Market Access: New Hep C Approach Might Not Save Money, PBM Execs Warn

Radar On Market Access: PBMs May Be Able to Handle Pressure From State Medicaid Programs

MMIT Reality Check on Immune Globulin PID (Jan 2019)

Trends That Matter for Migraine Drugs

Radar On Market Access: Judge OKs CVS Plan to Keep Aetna Separate Pending Review

MMIT Reality Check on Epilepsy (Dec 2018)

Perspectives on Drug-Price Action

Radar On Market Access: GAO Recommends FDA Improve Orphan Label Application Reviews

MMIT Reality Check on Alpha-1 Antitrypsin Deficiency (Dec 2018)

Trends That Matter for Crohn's Disease Medications

Radar On Market Access: New PBM Models Respond to Public Pressure, Market Demand

Radar On Market Access: FDA Approves Second Tissue-Agnostic Drug; Refund Is Available

MMIT Reality Check on Prostate Cancer (Dec 2018)

Perspectives on FDA’s Approval of New Opioid Formulation

Radar On Market Access: New MA Rule Touches Protected Classes, Imposes Pricing Tool

Radar On Market Access: Despite Threatening to Halt Integration, Judge Is Likely to Sign Off on CVS/Aetna Deal

MMIT Reality Check on Cystic Fibrosis (Dec 2018)

Trends That Matter for HIV Treatments

Radar On Market Access: Future of Potential Humana/ Walgreens Tie-Up Is Murky

Radar On Market Access: CMS's Second Swing at Part D Protected Classes Might Work

MMIT Reality Check on Growth Hormones (Nov 2018)

Perspectives on Proposed Part D Change

Radar On Market Access: New Migraine Drugs Could Spark Value-Based Contracting

Radar On Market Access: New Biosimilars Help Crohn’s Cost, but Boost Oversight Needs

MMIT Reality Check on Ovarian Cancer (Nov 2018)

Trends That Matter for Drug Prices

Radar On Market Access: Count on Trump Admin, not Congress, for Drug-Price Action

Radar On Market Access: Prime PBM's Studies Show Promise for Managing Opioids

MMIT Reality Check on Migraine (Nov 2018)

Perspectives on MA Plans’ Use of Step Therapy in Part B

Radar On Market Access: FDA’s OK of Opioid Makes ‘Diversion of Even One Tablet’ Risky

Radar On Market Access: CVS, Cigna Preview What’s in Store After Their Deals Close

MMIT Reality Check on Multiple Myeloma (Nov 2018)

Trends That Matter for Sensor-Equipped Pills

Radar On Market Access: New Opioid Law Has Implications for MA, Medicaid Plans

Radar On Market Access: PhRMA, Feds Spar Over Where To Place Drug Pricing Details

MMIT Reality Check on CLL (Nov 2018)

Perspectives on CVS Bid to Lower Drug Launch Prices

Radar On Market Access: Express Scripts Exec Urges Smarter Treatment of HIV

Radar On Market Access: Proposed Part D Change Might Not Be “Catastrophic”

MMIT Reality Check on Hypertension (Oct 2018)

Radar On Market Access: IL-17 Inhibitors Becoming More Popular as a First-Line Therapy, Study Finds

Trends That Matter for Epilepsy Medications

Radar On Market Access: UnitedHealth Bolsters OptumRx With Genoa Buy

MMIT Reality Check on Respiratory (Asthma/COPD) (Oct 2018)

Radar On Market Access: Drug Prices Increases Are Expected to Slow

Perspectives on Indication-Based Formularies in Part D

Radar On Market Access: Opinions Vary on MA Plans’ Use of Step Therapy in Part B

MMIT Reality Check on Hepatitis C (Oct 2018)

Trends That Matter for Specialty Drug Management

Radar On Market Access: Prime’s New Formulary Excludes Many Drugs Just Added in 2018

Radar On Market Access: Once Deal Closes, What’s Next for Cigna/Express Scripts?

MMIT Reality Check on Hereditary Angioedema (Sep 2018)

Radar On Market Access: Plans Might Tap Utilization Management for Marijuana-Derived Epilepsy Drug

Perspectives on Express Scripts’ 2019 National Preferred Formulary

Radar On Market Access: Payers Wait for Gilead’s HCV Generics to Hit Market Soon

MMIT Reality Check on HIV (Sep 2018)

Trends That Matter for 2019 PBMs' Exclusions

Radar On Market Access: CVS Bid to Lower Drug Launch Prices Sees Pushback

Radar On Market Access: Sensor-Equipped Pills Draw Plans’ Interest

MMIT Reality Check on Rheumatoid Arthritis (Sep 2018)

Perspectives on Step Therapy for Part B Drugs

Radar On Market Access: NASHP Unveils PBM Model Act

Radar On Market Access: Indication-Based Formularies in Part D

MMIT Reality Check on Diabetes (Sep 2018)

Trends That Matter for Epinephrine Medications

Radar On Market Access: Express Scripts’ 2019 National Preferred Formulary

Radar On Market Access: Patients' Perspectives in Value Assessment

MMIT Reality Check on G-CSF (Sep 2018)

Perspectives on New Class of Migraine Drug

Radar On Market Access: Failed Albertsons/Rite Aid Deal

Radar On Market Access: Specialty Drug Management Continues to Concern Employers

MMIT Reality Check on Hemophilia (Aug 2018)

Radar On Market Access: PBM’s 2019 Formulary Exclusions

Trends That Matter for Global Oncology

Radar On Market Access: New EpiPen Generic May Avert Shortages

MMIT Reality Check on PCSK9 (Aug 2018)

Perspectives on Massachusetts’ Medicaid Drug Pricing Plan Rejection

Radar On Market Access: Alnylam Launches New Gene Silencing Drug

Radar On Market Access: Medical and Pharmacy Benefits of Ovarian Cancer Drugs

MMIT Reality Check on Multiple Sclerosis (Aug 2018)

Trends That Matter for Multiple Myeloma Therapies

Radar On Market Access: Shingrix Remains in Short Supply

Radar On Market Access: Step Therapy for Part B Drugs

MMIT Reality Check on Tardive Dyskinesia (Aug 2018)

Perspectives on REMS Programs

Radar On Market Access: New Class of Migraine Drug Drives Changes

Radar On Market Access: Drug-Diagnostic Co-Development

MMIT Reality Check on Crohn's Disease (Aug 2018)

Trends That Matter for Generic Drugs

Radar On Market Access: Generic Firm as "Societal Asset"

Radar On Market Access: FDA Aims to Give Biosimilars a Boost

MMIT Reality Check on IVIG (Jul 2018)

Perspectives on Amazon/PillPack Deal

Radar On Market Access: Initiative Focuses on T790M Mutation

Radar On Market Access: Varied Multiple Myeloma Therapies Exist

MMIT Reality Check on Epilepsy (Jul 2018)

Radar On Market Access: CMS Denies Massachusetts' Medicaid Drug Pricing Plan

Trends That Matter for Specialty Pharmaceuticals' Managed Care Strategies

Radar On Market Access: Clover Health Offers Pharmacogenomics Testing

MMIT Reality Check on Alpha-1 Antitrypsin Deficiency (Jul 2018)

Perspectives on Value-Based Contracts

Radar On Market Access: Amazon/PillPack Deal Has Limited Effect

Radar On Market Access: Centene Highlights New PBM Asset

MMIT Reality Check on Advanced Prostate Cancer (Jul 2018)

Trends That Matter for Drug Cost

Radar On Market Access: Pharma Can Use REMS Programs to its Advantage

Radar On Market Access: Gene Therapies Pose Challenges

MMIT Reality Check on Cystic Fibrosis (Jun 2018)

Perspectives on Outcomes-Based Drug Pricing

Radar On Market Access: FDA Acts to Speed Generics to Market

Radar On Market Access: FDA Guidance Give More Comfort for Payer VBCs

MMIT Reality Check on Growth Hormones (Jun 2018)

Radar On Market Access: Prime's New Platform Targets Fraud, Waste and Abuse

Radar On Market Access: Biosimilars' Change in Part D

MMIT Reality Check on Multiple Myeloma (Jun 2018)

Radar on Market Access: Global Oncology Trends

Radar on Market Access: IngenioRx Drug Trend Report

Radar On Market Access: In Value-Based Deals, Idea of Value Differs Among Firms

Radar On Market Access: Value of Device-Gathered Data to Regulatory Agencies

MMIT Reality Check on Chronic Lymphocyctic Leukemia

MMIT Reality Check on Atopic Dermatitis (May 2018)

Radar On Market Access: Pharma Faces Limits When Providing Payers Drug Information

Radar On Market Access: Express Scripts Inks Deal with Praluent Manufacturers

Radar On Market Access: Drug Cost Transparency Service

Radar On Market Access: Managed Care Strategies for Specialty Pharmaceuticals

MMIT Reality Check on Psoriasis (Q2 2018)

Radar On Market Access: American Patients First Blueprint

Radar On Market Access: Outcomes-Based Drug Pricing

MMIT Reality Check on Hypertension (Q2 2018)

Radar On Market Access: CMS Targets Opioid Utilization

Radar On Market Access: Pharma's Role in Prior-Authorization Conflict

Radar On Market Access: CVS’s Chronic Kidney Disease Program

MMIT Reality Check on Respiratory (Asthma/COPD) (May 2018)

Radar On Market Access: Statin Gender Bias

Radar on Market Access: Specialty Drug Spend

Radar On Market Access: Psoriasis Therapies

MMIT Reality Check on Viscosupplements (Apr 2018)

Radar On Market Access: Opioid Crisis

Radar On Market Access: New Financing Strategies for Innovative Therapies

MMIT Reality Check on Hepatitis C (Apr 2018)

Radar On Market Access: Managing Specialty Drug Costs as Top Employer Concern

Radar On Market Access: Value-Based Pricing

MMIT Reality Check on Detoxification Agents (Apr 2018)

Radar On Market Access: Immuno-Oncology Drugs

Radar On Market Access: Senate Seeks to Bar "Gag Clauses"

MMIT Reality Check on Antipsychotics (Mar 2018)

Radar On Market Access: Pediatric and Adult Vaccines

Radar On Market Access: Copay Accumulator Programs

Radar On Market Access: Changes to Medicare Part D Coverage Gap

Radar On Market Access: Rebates for Specialty Drugs

MMIT Reality Check on Narcotic Pain (Mar 2018)

MMIT Reality Check on Immunology: Rheumatoid Arthritis (Mar 2018)

Trends That Matter for Drug Expenditures

Perspectives on Cigna-Express Scripts Deal

Trends That Matter for Pharma and Biotech Industry

Perspectives on Analytics Revolution in the Life Sciences Industry

Trends That Matter for Immune Globulin

Perspectives on 2018 Pipeline

Trends That Matter for Promising Drugs in 2018

Perspectives on NASH Market

MMIT Reality Check on Hereditary Angioedema (Feb 2018)

Trends That Matter for HIV

Perspectives on OTC Pharma Packaging

MMIT Reality Check on IVIG (Feb 2018)

Trends That Matter for Product Launch

Perspectives on Triggered Messages

MMIT Reality Check on HIV (Feb 2018)

Trends That Matter for Cystic Fibrosis

MMIT Reality Check on PCSK9 Inhibitors (Jan 2018)

Perspectives on R&D Budgets

Trends That Matter for Breast Cancer Treatment

MMIT Reality Check on Cystic Fibrosis (Jan 2018)

Perspectives on Payer Priorities in 2018

Trends That Matter for Compounding Policies

Perspectives on the Migraine Pipeline

Trends That Matter for HGH Treatments

Perspectives on Pharma Globalization

MMIT Reality Check on Growth Hormones (Jan 2018)

Trends That Matter for Pain Relief

Perspectives on Drug Naming Policies

MMIT Reality Check on Diabetes (Dec 2017)

Which Disease Areas Are On Your Mind Going Into 2018?

Trends That Matter for Hypertension

Perspectives on Wearable Device Data

Trends That Matter for BCBS Plans

MMIT Reality Check on Hemophilia (Dec 2017)

Perspectives on Kidney Cancer

Trends That Matter for Viscosupplements

Perspectives on Marketing to Millennials

Trends That Matter for Multiple Sclerosis

Perspectives on the Anti-Epilepsy Pipeline

MMIT Reality Check on Multiple Sclerosis (Nov 2017)

Trends That Matter for G-CSF Treatments

Perspectives on Digital Disruption

Trends That Matter for M&A Activity

MMIT Reality Check on G-CSF (Nov 2017)

Trends That Matter for Chronic Heart Failure

Perspectives on Twitter Marketing

Trends That Matter for Acne Treatment

MMIT Reality Check on Heart Failure (Nov 2017)

Perspectives on Real-World Data

Trends That Matter for Pharma Manufacturing

Perspectives on Specialty Pharmacies

MMIT Reality Check on Dermatology: Acne (Oct 2017)

Trends That Matter for Narcotic Pain Treatment

Perspectives on Payer Trends

MMIT Reality Check on Viscosupplements (Oct 2017)

Trends That Matter for the Specialty Pharma Sector

Perspectives on Biopharmaceutical R&D

Trends That Matter for Antipsychotic Treatments

Perspectives on Value Frameworks

Formulary Coverage Changes for 2018 Medicare

MMIT Reality Check on Respiratory (Asthma/COPD) (Oct 2017)

Trends That Matter for STEM Opportunities

MMIT Reality Check on Antipsychotics (Oct 2017)

Perspectives on Pharma Sales Planning

MMIT Reality Check on Detoxification Agents (Oct 2017)

Trends That Matter for Customer Centricity in Pharma

Perspectives on Top Therapy Areas

Trends That Matter for Social Engagement

MMIT Reality Check on Hepatitis C (Sep 2017)

Perspectives on Payer Engagement Strategies

Trends That Matter for Hereditary Angioedema

Perspectives on 2017 Approvals

MMIT Reality Check on Narcotic Pain (Sep 2017)

Trends That Matter for Medical AI

Perspectives on Recognizing Signs of Change

Trends That Matter for Heart Disease Treatment

MMIT Reality Check on Immunology: Rheumatoid Arthritis (Aug 2017)

Perspectives on Field Force Excellence

Trends That Matter for Psoriasis Treatment

MMIT Reality Check on Hereditary Angioedema (Aug 2017)

Perspectives on Competing in Highly-Managed Classes

MMIT Reality Check on Immune Globulin (Aug 2017)

Trends That Matter for Pharma Dealmaking

Top Market Access, Policy and Restriction Posts from 2017

Perspectives on Consistent Physical & Digital Assets

MMIT Reality Check on HIV (Aug 2017)

Trends That Matter for CMS Proposed Guidelines

MMIT Reality Check on PCSK9 Inhibitors (Aug 2017)

Perspectives on Payer Market Events

Trends That Matter for Off-Label Drug Use

Perspectives on Translating Data into Powerful Stories

MMIT Reality Check on Cystic Fibrosis (Jul 2017)

Trends That Matter for Transforming Clinical Trials

Perspectives on Patient Support Programs

Trends That Matter for Monitoring Chronic Conditions

MMIT Reality Check on Growth Hormones (Jul 2017)

Perspectives on Optimizing Your "Superfans"

MMIT Reality Check on Diabetes (Jul 2017)

Trends That Matter for Digital Health

Perspectives on Crowded Disease Areas

Trends That Matter for Supply Chain Innovation

Trends That Matter for Wearables

MMIT Reality Check on Multiple Sclerosis (Jun 2017)

Perspectives on Overcoming Generic Objections

Trends That Matter for Biosimilars

MMIT Reality Check on Hemophilia (Jun 2017)

Perspectives on Medical Benefit Evolution

MMIT Reality Check on G-CSF (Jun 2017)

Trends That Matter for Global Health

MMIT Reality Check on Heart Failure (Jun 2017)

Perspectives on the Role of HCP Office Staff

Trends That Matter for Pharma's Economic Footprint

Perspectives on the Velocity of Payer Access Shifts

MMIT Reality Check on Dermatology: Acne (June 2017)

Trends That Matter for Sales Training

Perspectives on Pharma Field Team Mapping

Trends That Matter for the Healthcare Industry in 2017

Perspectives on Prescriber Personas

Trends That Matter for Pharma Brands on Social Media

MMIT Reality Check on Viscosupplements (May 2017)

Perspectives on the Role of Market Access in Drug Launches

Trends That Matter for Prescription Pricing

Perspectives on New to Market Policies

Perspectives on Getting New Drugs to Market

MMIT Reality Check on Respiratory (Asthma/COPD) (May 2017)

Trends That Matter for Biomarker Research

MMIT Reality Check on Atypical Antipsychotics (Apr 2017)

Trends That Matter for Technology Integration

Perspectives on Change Management in Pharma

MMIT Reality Check on Detoxification Agents (Apr 2017)

Trends That Matter for Global Life Sciences

Perspectives on Pharmacy Benefit Evolution

MMIT Reality Check on Hepatitis C (Apr 2017)

Trends That Matter for Alzheimer’s Diagnosis

Perspectives on Simplifying Reimbursement Restrictions

MMIT Reality Check on Narcotic Pain (Apr 2017)

Trends That Matter for Cancer Spending

Perspectives on Preferred and Exclusion Lists

Trends That Matter for Medicare Challenges

Perspectives on Payer Leverage

MMIT Reality Check on Immunology: Rheumatoid Arthritis (Mar 2017)

Market Access is Getting Harder

Trends That Matter for Pharma Data

MMIT Reality Check on Hereditary Angioedema (Mar 2017)

Perspectives on Consumer Marketing

Trends That Matter for the Health Insurance Exchange

Perspectives on the Value of Rebates

MMIT Reality Check on Immune Globulin (Mar 2017)

Trends That Matter for Pharma Advertising

Perspectives on Field Force Mapping

Top 5 Formulary Challenges for 2017

Trends That Matter for Specialty Pharmacy

Perspectives on Pre-Call Planning and eDetailing in Pharma Sales

MMIT Reality Check on HIV Transcriptase

MMIT Reality Check on PCSK9 Inhibitors (Feb 2017)

Trends That Matter for Phase 3

Perspectives on Managed Care Trends

Trends That Matter for Physician Engagement

Perspectives on Payer Contracting

MMIT Reality Check on Cystic Fibrosis (Feb 2017)

Trends That Matter for Brand Marketing

Perspectives on Health Exchange Shifts

Trends That Matter for High Deductible Health Plans

Perspectives on Tracking Competition

MMIT Reality Check on Growth Hormones (Jan 2017)

Trends That Matter for Big Data in Pharma

Top Market Access Posts from 2016

Perspectives on Medicare Coverage

Trends That Matter for Market Access in Trending Classes

Perspectives on Social Media in Pharma

MMIT Reality Check on Diabetes (Jan 2017)

MMIT Reality Check on Multiple Sclerosis (Jan 2017)

Trends That Matter for Orphan Drugs

Perspectives on 2017 Drug Pipelines

MMIT Reality Check on Hemophilia (Jan 2017)

Trends That Matter for 2016 Approvals

Perspectives on Biosimilar Development

Perspectives on HCP Facetime Challenges

Trends That Matter for Integrated Specialty Networks

MMIT Reality Check on G-CSF (Dec 2016)

Trends That Matter for Managed Markets

Perspectives on High Deductible Health Plan Strategy

MMIT Reality Check on Heart Failure (Dec 2016)

Formulary Search Update: December 2016

Trends That Matter for Prescriber Communication

Perspectives on Medical Benefits and Restrictions

MMIT Reality Check on Dermatology: Acne (Dec 2016)

The Devil is in the Details

Trends That Matter for Drug Compliance

Perspectives on Late Phase Pipeline Awareness

Trends that Matter for Healthcare Leaders

Perspectives on Pre-call Planning & eDetailing

Trends that Matter for Standardized Healthcare

MMIT Reality Check on Viscosupplements (Nov 2016)

Perspectives on Provider Data Consistency

MMIT Reality Check on Respiratory (Asthma/COPD) (Nov 2016)

Trends that Matter for Personal Promotion

Perspectives on Biologic Coverage

MMIT Reality Check on Atypical Antipsychotics

Trends that Matter for Consolidation

Perspectives on Drug Launch Marketing

MMIT Reality Check on Hereditary Angioedema (Oct 2016)

Trends that Matter for Highly Managed Classes

Perspectives on Integrated Specialty Networks

MMIT Reality Check on Detoxification Agents (Oct 2016)

Trends that Matter for Biobetters

Perspectives on Prescriber Targeting

MMIT Reality Check on Hepatitis C (Oct 2016)

Trends that Matter for Payer & PBM Innovation

Perspectives on Payer Contracting

Trends that Matter for Non Personal Promotion

MMIT Reality Check on Narcotic Pain (Oct 2016)

Perspectives on Omnichannel Promotion

MMIT Reality Check on Rheumatoid Arthritis

Trends that Matter for FDA Regulation

Perspectives on Value-Based Care Shift

MMIT Reality Check on Immune Globulin (Oct 2016)

Trends that Matter in Healthcare IT Systems

Perspectives on Biosimilar Pricing

Trends that Matter for Influencer Marketing in Healthcare

MMIT Reality Check on HIV (Sep 2016)

Trends that Matter for Pharmacist Influence

Perspectives on Formulary Storytelling

MMIT Reality Check on PCSK9 Inhibitors (Sep 2016)

Perspectives on Sales Messaging (Pt. 2)

Perspectives on Sales Messaging (Pt. 1)

Formulary Search 2.5 Years In

Numbers that Matter in Patient Centricity

MMIT Reality Check on Cystic Fibrosis (September 2016)

Perspectives on PBM Consolidation (Pt. 2)

Perspectives on PBM Consolidation (Pt. 1)

Trends that Matter for Social Media in Healthcare

Perspectives on Outsourcing Data Systems

MMIT Reality Check on Growth Hormones (August 2016)

Perspectives on Orphan Drug Reimbursement (Pt. 2)

Trends that Matter for Pharma Pipeline Development

Perspectives on Orphan Drug Reimbursement (Pt. 1)

MMIT Reality Check on Diabetes (August 2016)

Perspectives on Biosimilar Marketing (Pt. 2)

Perspectives on Biosimilar Marketing (Pt. 1)

Perspectives on Emerging Pharma Competition (Pt. 2)

MMIT Reality Check on Multiple Sclerosis (Aug 2016)

Trends that Matter in Specialty Pharmacy Networks

Formulary Search App: Now Available on Android

Perspectives on Emerging Pharma Competition (Pt. 1)

Trends that Matter for Mobile Healthcare Apps

Perspectives on Big Data in Pharmaceuticals

MMIT Reality Check on Hemophilia (July 2016)

Trends that Matter for Commercial, Health Exchange & Medicare Market Access

Perspectives on Managed Markets Innovation

MMIT Reality Check on G-CSF

Trends that Matter for Pharmaceutical Drug Development

Perspectives on Payer Marketing: Part 2

Perspectives on Payer Marketing

Trends that Matter for the Modern Healthcare Consumer

Perspectives on Pharmaceutical Drug Compliance: Part 2

MMIT Reality Check on Heart Failure

Perspectives on Pharmaceutical Drug Compliance: Part 1

Perspectives on Integrated Technology and Systems

Trends that Matter for Healthcare Analytics

MMIT Reality Check on Dermatology: Acne (July 2016)

Trends that Matter for Value-Based Care

MMIT Reality Check on Viscosupplements (June 2016)

Perspectives on Pharmacist Engagement

Live Free or Die Hard

Trends that Matter for Orphan Drug Landscapes

Perspectives on Prescriber and HCP Engagement

MMIT Reality Check on Respiratory (Asthma/COPD) (June 2016)

Trends that Matter for Patient and Provider Education

Perspectives on Healthcare Networking Events

MMIT Reality Check on Antipsychotics (June 2016)

Trends that Matter for Managed Care Coverage

Perspectives on Pharmaceutical Communication Channels II

Perspectives on Pharmaceutical Communication Channels

Perspectives on Integrated Associations in Healthcare (Continued)

MMIT Reality Check on Hereditary Angioedema (June 2016)

Trends that Matter for Healthcare Economics

Perspectives on Integrated Associations in Healthcare

MMIT Reality Check on Detoxification Agents (May 2016)

Trends that Matter for Health Exchange Coverage

Perspectives on Influencer Marketing in Healthcare

MMIT Reality Check on HIV (May 2016)

Trends that Matter for Digital Prescribers

Perspectives on Healthcare Regulatory Agencies

MMIT Reality Check on Hepatitis C (May 2016)

Perspectives on Healthcare Leadership

Trends that Matter for Social Pharma

MMIT Reality Check on Immune Globulin (May 2016)

Trends that Matter for Medicare Coverage

Perspectives on Big Data in Healthcare

MMIT Reality Check on PCSK9 Inhibitors (April 2016)

Trends that Matter for Healthcare IT

Perspectives on the Effects of Rising Healthcare Costs

MMIT Reality Check on Cystic Fibrosis (April 2016)

Trends that Matter for Big Pharma Executives

Perspectives on Innovative Interoperability

Fast and Furious: Keeping up with Hemophilia

MMIT Reality Check on Growth Hormones (April 2016)

Trends that Matter for Drug Pipeline Development

Perspectives on Leveraging Payer Relationships

Formulary Navigator Highlights 2015

Perspectives on Consumer Marketing: Part 2

MMIT Reality Check on Narcotic Pain (April 2016)

Trends that Matter for mHealth

Perspectives on Consumer Marketing: Part 1

Perspectives on Pharma Marketing: Part 2

MMIT Reality Check on Diabetes (March 2016)

Trends that Matter for Step Therapies

Perspectives on Pharma Marketing: Part 1

MMIT Reality Check on Multiple Sclerosis (March 2016)

Trends that Matter in Physician Challenges

The Biosimilar Show: The Hottest Show to Watch

The Pending U.S. Biosimilar Wave and Interchangeability

Perspectives on Pharma Field Force Strategy: Part 2

MMIT Reality Check on Immunology (March 2016)

Trends that Matter in Accountable Care

Perspectives on Pharma Field Force Strategy: Part 1

Perspectives on Non-Personal Promotion: Part 2

MMIT Reality Check on Hemophilia (March 2016)

Trends that Matter in Specialty Pharmacy

Perspectives on Non-Personal Promotion: Part 1

MMIT Reality Check on IBS Treatments

Trends that Matter for Pharmaceutical Advertising

Planes, Wi-Fi and Medication

Perspectives on Driving Payer Engagement

The Real Cost of Hepatitis C Treatment: Part 2

MMIT Reality Check on ED Treatments

Trends that Matter for Prior Authorizations

The Real Cost of Hepatitis C Treatment: Part 1

Formulary Lookup Update: February 2016

Fear and Loathing in Pharma

MMIT Reality Check on Testosterone

Trends that Matter for Restricted Therapeutic Areas

Perspectives on Payer and PBM Innovation

Trends that Matter for Physician Engagement

MMIT Reality Check on Antidepressants

Perspectives on Health Insurance Exchange Developments

MMIT Reality Check on Dermatology: Acne

Trends that Matter for High Deductible Health Plans

Perspectives on Managed Care Strategies

Trends that Matter for Big Data Challenges

Data Quality Has Huge Implications - Just Ask Regeneron

MMIT Reality Check on Antipsychotics

Perspectives on Growing Drug Pipelines

Enhanced Data Sharing Adoption & Improvements in Interoperability

Perspectives on Biobetters

Trends that Matter for Physician Marketing

Perspectives on Big Pharma's Focus Therapeutic Areas

MMIT Reality Check on Asthma/COPD Treatments

Trends that Matter for Market Access in Trending Classes

Trends that Matter for Biosimilars and Orphan Drugs

MMIT Reality Check on Viscosupplements

Perspectives on Biosimilar Development

Trends that Matter for 2015 Approvals

MMIT Reality Check on Hereditary Angioedema

Perspectives on Evolving Benefit Designs

MMIT Reality Check on Hepatitis C

Trends that Matter for Formulary Insights

Perspectives on Standardized Healthcare

Formulary Search Update: December 2015

MMIT Reality Check on Detoxification Agents

Trends that Matter in Healthcare Data Security

Perspectives on Value-Based Care

Numbers that Matter in Medicare

MMIT Reality Check on PCSK9 Inhibitors

Perspectives on Medicare Access

Numbers that Matter in Digital Health

MMIT Reality Check on HIV

Perspectives on the Affordable Care Act

Numbers that Matter in Pharma Sales

MMIT Reality Check on Narcotic Pain

Perspectives on Healthcare Consolidation

Numbers that Matter in Highly Managed Classes

MMIT Reality Check on Cystic Fibrosis

Perspectives on Unique Manufacturer Strategies

Numbers that Matter in Patient Big Data

MMIT Reality Check on Immune Globulin

Perspectives on Reimbursement Restrictions

Numbers that Matter in Patient Engagement

MMIT Reality Check on Growth Hormones

Perspectives on Physician Engagement

Numbers that Matter in Marketing Healthcare

MMIT Reality Check on Diabetes

Perspectives on Healthcare Transparency

Numbers that Matter in Big Data for Healthcare

MMIT Reality Check on Multiple Sclerosis

Perspectives on Specialty Drug Pipelines

Numbers that Matter in the Healthcare Network

MMIT Reality Check on DMARDs

Perspectives on Healthcare Oversight & Regulation

Numbers that Matter in Specialty Drug Pipelines

MMIT Reality Check on Hemophilia

Perspectives on Highly Managed Class Restrictions

Numbers that Matter in Drug Marketing

MMIT Policy & Restriction Analytics Release on September 28th

Perspectives on Top Highly Managed Classes

Numbers that Matter in Healthcare Marketing

Perspectives on Specialty Drug Pricing

Trends that Matter in Specialty Pharma

Biosimilar Reality Check? Payer, Pharma & Provider Perspectives

Market Access in Kidney Cancer

Market Access in Disease Modifying Agents

Market Access in Multiple Sclerosis

Market Access in Breast Cancer

The Trajectory of Oncology

All posts